OVID

Company Overview — What Does Ovid Therapeutics Inc. Do?

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. Ovid Therapeutics Inc. (OVID) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Jeremy M. Levin and employs approximately 60 people. With a market capitalization of $326M, OVID is one of the notable companies in the Healthcare sector.

Ovid Therapeutics Inc. (OVID) Stock Rating — Hold (April 2026)

As of April 2026, Ovid Therapeutics Inc. receives a Hold rating with a composite score of 38.1/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.OVID ranks #1,078 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Ovid Therapeutics Inc. ranks #77 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

OVID Stock Price and 52-Week Range

Ovid Therapeutics Inc. (OVID) currently trades at $2.84. The stock lost $0.04 (1.4%) in the most recent trading session. The 52-week high for OVID is $2.50, which means the stock is currently trading 13.6% from its annual peak. The 52-week low is $0.24, putting the stock 1071.1% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is OVID Overvalued or Undervalued? — Valuation Analysis

Ovid Therapeutics Inc. (OVID) carries a value factor score of 23/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.96x, versus the sector average of 2.75x. The price-to-sales ratio is 57.65x, compared to 1.66x for the average Healthcare stock.

At current multiples, Ovid Therapeutics Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Ovid Therapeutics Inc. Profitability — ROE, Margins, and Quality Score

Ovid Therapeutics Inc. (OVID) earns a quality factor score of 25/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -31.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -27.2% versus the sector average of -33.1%.

On a margin basis, Ovid Therapeutics Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -6716.7% (sector: -66.1%). Net profit margin stands at -6313.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -21.9% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

OVID Debt, Balance Sheet, and Financial Health

Ovid Therapeutics Inc. has a debt-to-equity ratio of 16.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 8.97x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $21M.

OVID has a beta of 1.50, meaning it is more volatile than the broader market — a $10,000 investment in OVID would be expected to move 50.5% more than the S&P 500 on any given day. The stability factor score for Ovid Therapeutics Inc. is 21/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Ovid Therapeutics Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Ovid Therapeutics Inc. reported revenue of $7M. Net income for the quarter was $-41M. Gross margin was 100.0%. Operating income came in at $-43M.

In FY 2025, Ovid Therapeutics Inc. reported revenue of $7M. Net income for the quarter was $-17M. Revenue grew 1181.3% year-over-year compared to FY 2024. Operating income came in at $-42M.

In Q3 2025, Ovid Therapeutics Inc. reported revenue of $132,000. Net income for the quarter was $-12M. Revenue grew -23.7% year-over-year compared to Q3 2024. Operating income came in at $-13M.

In Q2 2025, Ovid Therapeutics Inc. reported revenue of $6M and earnings per share (EPS) of $-64.79. Net income for the quarter was $-5M. Gross margin was 100.0%. Revenue grew 3611.2% year-over-year compared to Q2 2024. Operating income came in at $-5M.

Over the past 8 quarters, Ovid Therapeutics Inc. has demonstrated a growth trajectory, with revenue expanding from $169,000 to $7M. Investors analyzing OVID stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

OVID Dividend Yield and Income Analysis

Ovid Therapeutics Inc. (OVID) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

OVID Momentum and Technical Analysis Profile

Ovid Therapeutics Inc. (OVID) has a momentum factor score of 74/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 38/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 30/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

OVID vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Ovid Therapeutics Inc. (OVID) ranks #77 out of 838 stocks based on the Blank Capital composite score. This places OVID in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing OVID against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full OVID vs S&P 500 (SPY) comparison to assess how Ovid Therapeutics Inc. stacks up against the broader market across all factor dimensions.

OVID Next Earnings Date

No upcoming earnings date has been announced for Ovid Therapeutics Inc. (OVID) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy OVID? — Investment Thesis Summary

Ovid Therapeutics Inc. presents a balanced picture with arguments on both sides. The quality score of 25/100 flags below-average profitability. The value score of 23/100 indicates premium valuation. Price momentum is positive at 74/100, suggesting the trend favors buyers. High volatility (stability score 21/100) increases portfolio risk.

In summary, Ovid Therapeutics Inc. (OVID) earns a Hold rating with a composite score of 38.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on OVID stock.

Related Resources for OVID Investors

Explore more research and tools: OVID vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare OVID head-to-head with peers: OVID vs AZN, OVID vs SLGL, OVID vs VMD.